Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,433

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Mycophenolate mofetil and its mechanisms of action

Allison, Anthony C, Eugui, Elsie M·2000·Immunopharmacology
DOI 10.1016/s0162-3109(00)00188-0
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0162-3109(00)00188-0

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 151

  1. Al-Akash, 1998, Influenza vaccine antibody response in pediatric renal transplant patients treated with newer immunosuppressive agents, J. Am. Soc. Nephrol., 9, 663A
  2. Alfieri, 1994, Effect of mycophenolic acid on Epstein–Barr virus infection of human B-lymphocytes, Antimicro. Agents Chemother., 38, 126, 10.1128/AAC.38.1.126 · doi:10.1128/aac.38.1.126
  3. Allison, 2000, Immunosuppressive drugs: the first 50 years and a glance forward, Immunopharmacology, 47, 63, 10.1016/S0162-3109(00)00186-7 · DOI · Paper page
  4. Allison, 1991, In vitro immunosuppressive effects of mycophenolic acid and an ester prodrug, RS-61443, Transplant. Proc., 23, 10
  5. Allison, 1993, The design and development of an immunosuppressive drug, mycophenolate mofetil, Springer Semin. Immunopathol., 14, 353, 10.1007/BF00192309 · DOI
  6. Allison, 1975, Immunological observations on patients with the Lesch–Nyhan syndrome, and on the role of de novo purine synthesis in lymphocyte transformation, Lancet, II, 1179, 10.1016/S0140-6736(75)92661-6 · DOI
  7. Allison, 1977, The role of de novo purine synthesis in lymphocyte transformation, Ciba Found. Symp., 48, 207
  8. Allison, 1993, Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules, Transplant. Proc., 25, 67
  9. Altmann, 1989, Cotransfection of ICAM-1 and HLA-DR reconstitutes human antigen-presenting function in mouse L cells, Nature, 338, 512, 10.1038/338512a0 · DOI · Paper page
  10. Ando, 1997, Perforin, Fas/Fas ligand and TNF-α pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL, J. Immunol., 158, 5283, 10.4049/jimmunol.158.11.5283 · DOI · Paper page
  11. Azuma, 1995, Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts, Transplantation, 59, 460, 10.1097/00007890-199502270-00002 · doi:10.1097/00007890-199502270-00002
  12. Bagasra, 1995, Activation of the inducible nitric oxide synthase in brains of patients with multiple sclerosis, Proc. Natl. Acad. Sci. U. S. A., 92, 12041, 10.1073/pnas.92.26.12041 · DOI · Paper page
  13. Benvenuti, 1996, Increased serum nitrate concentration in cardiac transplant patients. A marker for acute allograft cellular rejection, Transplantation, 61, 745, 10.1097/00007890-199603150-00013 · DOI
  14. Berman, 1982, In vitro effects of mycophenolic acid and allopurinol against Leishmania tropica in human macrophages, Antimicro. Agents Chemother., 21, 887, 10.1128/AAC.21.6.887 · doi:10.1128/aac.21.6.887
  15. Birkeland, 1988, Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy, Transplantation, 66, 1207, 10.1097/00007890-199811150-00016 · doi:10.1097/00007890-199811150-00016
  16. Blaheta, 1999, Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells, Transplant. Proc., 31, 1250, 10.1016/S0041-1345(98)01984-8 · DOI
  17. Böhm, 1997, Bullous pemphigoid treated with mycophenolate mofetil, Lancet, 349
  18. Borel, 1976, Biological effects of cyclosporein A: a new anti-lymphocyte agent, Agents Actions, 6, 468, 10.1007/BF01973261 · DOI · Paper page
  19. Briggs, 1998, Successful mycophenolate mofetil treatment of glomerular disease, Am. J. Kidney Dis., 31, 213, 10.1053/ajkd.1998.v31.pm9469489 · doi:10.1053/ajkd.1998.v31.pm9469489
  20. Brunner, 1988, Quantitative assay of the lytic interaction of murine lymphoma cells on 51Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and drugs, J. Immunol., 14, 181
  21. Carr, 1993, Characterization of human type I and type II IMP dehydrogenases, J. Biol. Chem., 268, 27286, 10.1016/S0021-9258(19)74247-1 · DOI · Paper page
  22. Chanaud, 1995, Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism, Exp. Eye Res., 61, 429, 10.1016/S0014-4835(05)80138-1 · DOI
  23. Chang, 1993, Brequinar sodium, mycophenolic acid, and cyclosporin A inhibit different stages of IL-4 or IL-3-induced human IgG4 and IgE production in vitro, Ann. N. Y. Acad. Sci., 696, 108, 10.1111/j.1749-6632.1993.tb17146.x · doi:10.1111/j.1749-6632.1993.tb17146.x
  24. Cohn, 1996, Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines, Transplantation, 68, 411, 10.1097/00007890-199908150-00014 · doi:10.1097/00007890-199908150-00014
  25. Corna, 1997, Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease, Kidney Int., 51, 1583, 10.1038/ki.1997.217 · doi:10.1038/ki.1997.217
  26. Dissanayake, 1998, Mycophenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat, Transplantation, 65, 275, 10.1097/00007890-199801270-00025 · DOI
  27. Dodge, 1999, Rapamycin induces TGF-β production in lymphocytes, Transplantation, 67, S50, 10.1097/00007890-199904150-00203 · doi:10.1097/00007890-199904150-00203
  28. Enk, 1998, Treatment of relapsing idiopathic nodular panniculitis (Pfeiffer–Weber–Christian disease) with mycophenolate mofetil, J. Am. Acad. Dermatol., 39, 508, 10.1016/S0190-9622(98)70340-8 · doi:10.1016/s0190-9622(98)70340-8
  29. Enk, 1999, Mycophenolate mofetil is effective in the treatment of pemphigus vulgaris, Arch. Dermatol., 135, 54, 10.1001/archderm.135.1.54 · doi:10.1001/archderm.135.1.54
  30. Eugui, 1991, Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion, Scand. J. Immunol., 33, 161, 10.1111/j.1365-3083.1991.tb03746.x · doi:10.1111/j.1365-3083.1991.tb03746.x
  31. Eugui, 1991, Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice, Scand. J. Immunol., 33, 175, 10.1111/j.1365-3083.1991.tb03747.x · doi:10.1111/j.1365-3083.1991.tb03747.x
  32. Fairbanks, 1995, Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors, J. Biol. Chem., 270, 29682, 10.1074/jbc.270.50.29682 · DOI · Paper page
  33. Franklin, 1969, The inhibition of nucleic acid synthesis by mycophenolic acid, Biochem. J., 113, 515, 10.1042/bj1130515 · DOI · Paper page
  34. Fraser-Smith, 1995, Suppression by mycophenolate mofetil of the neointimal thickening caused by vascular injury in a rat arterial stenosis model, J. Pharmacol. Exp. Ther., 275, 1204
  35. Fujihara, 1998, Mycophenolate mofetil attenuates renal injury in the rat remnant kidney, Kidney Int., 45, 1510, 10.1046/j.1523-1755.1998.00138.x · DOI · Paper page
  36. Garcia, 1977, Control of phosphoribosyl pyrophosphate synthesis in human lymphocytes, Biochem. Biophys. Res. Commun., 77, 1067, 10.1016/S0006-291X(77)80086-7 · doi:10.1016/s0006-291x(77)80086-7
  37. Geilen, 1998, Successful treatment of erythrodermic psoriasis with mycophenolate mofetil, Br. J. Dermatol., 138, 1101, 10.1046/j.1365-2133.1998.02296.x · doi:10.1046/j.1365-2133.1998.02296.x
  38. Giblett, 1972, Adenosine deaminase deficiency in two patients with severely impaired cellular immunity, Lancet, II, 1067, 10.1016/S0140-6736(72)92345-8 · DOI · Paper page
  39. Glinklich, 1998, Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide, Am. J. Kidney Dis., 32, 318, 10.1053/ajkd.1998.v32.pm9708620 · doi:10.1053/ajkd.1998.v32.pm9708620
  40. Goldblum, 1993, Therapy of rheumatoid arthritis with mycophenolate mofetil, Clin. Exp. Rheumatol., 11, S117
  41. Goto, 1997, Phenotype and localization of macrophages expressing inducible nitric oxide synthase in rat hepatic allograft rejection, Transplantation, 64, 303, 10.1097/00007890-199707270-00022 · DOI
  42. Grailer, 1991, Inhibition of human B cell responses in vitro by RS-61443, cyclosporine A and FK506, Transplant. Proc., 23, 314
  43. Green, 1978, Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin A treatment, Lancet, ii, 1182, 10.1016/S0140-6736(78)90970-4 · DOI · Paper page
  44. Green, 1979, Induction of specific tolerance in rabbits by kidney allografting and short period of cyclosporin A therapy, Lancet, ii, 123, 10.1016/S0140-6736(79)90005-9 · doi:10.1016/s0140-6736(79)90005-9
  45. Gregory, 1995, Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement, Transplantation, 59, 655, 10.1097/00007890-199503150-00002 · doi:10.1097/00007890-199503150-00002
  46. Gregory, 1988, Down regulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein–Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance, J. Exp. Med., 167, 1811, 10.1084/jem.167.6.1811 · DOI · Paper page
  47. Gregory, 1993, Effects of treatment with cyclosporine, FK-506, rapamycin, mycophenolic acid, or dexoyspergualin on vascular muscle proliferation in vitro and in vivo, Transplant Proc., 25, 770
  48. Grundmann-Kollman, 1999, Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases, J. Am. Acad. Dermatol., 40, 957, 10.1016/S0190-9622(99)70084-8 · doi:10.1016/s0190-9622(99)70084-8
  49. Hao, 1992, Facilitation of tolerance induction in adult mice by RS-61443, Transplantation, 53, 590, 10.1097/00007890-199203000-00020 · doi:10.1097/00007890-199203000-00020
  50. Hao, 1993, Mycophenolate mofetil can prevent the development of diabetes in BB rats, Ann. N. Y. Acad. Sci., 696, 328, 10.1111/j.1749-6632.1993.tb17168.x · doi:10.1111/j.1749-6632.1993.tb17168.x
  51. Hao, 1990, RS-61443 allows islet allografting and specific tolerance induction in adult mice, Transplant Proc., 22, 876
  52. Haufs, 1998, Psoriasis vulgaris treated successfully with mycophenolate mofetil, Br. J. Dermatol., 138, 179, 10.1046/j.1365-2133.1998.02048.x · doi:10.1046/j.1365-2133.1998.02048.x
  53. Hauser, 1999, Mycophenolate mofetil: therapeutic applications in kidney transplantation and immune-mediated renal disease, Curr. Opin. Nephrol. Hypertens., 8, 1, 10.1097/00041552-199901000-00001 · doi:10.1097/00041552-199901000-00001
  54. Hauser, 1998, Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil, Neurology, 51, 912, 10.1212/WNL.51.3.912-a · DOI
  55. Hauser, 1997, Effect of mycophenolic acid on TNF alpha-induced expression of cell adhesion molecules in human venous endothelial cells in vitro, Br. J. Pharmacol., 122, 1315, 10.1038/sj.bjp.0701517 · DOI
  56. Hauser, 1997, Mycophenolate mofetil, but not cyclosporin A or FK506, inhibits rat mesangial cell proliferation in vitro, J. Am. Soc. Nephrol., 9, 496A
  57. Häyry, 1993, Chronic allograft rejection, Immunol. Rev., 134, 33, 10.1111/j.1600-065X.1993.tb00639.x · DOI · Paper page
  58. Heemann, 1996, Mycophenolate mofetil inhibits lymphocyte binding and the upregulation of adhesion molecules in acute rejection of rat kidney allografts, Transplant. Immunol., 4, 64, 10.1016/S0966-3274(96)80039-6 · DOI
  59. Heering, 1998, MMF reduces proteinuria in passive Heymann nephritis, J. Am. Soc. Nephrol., 9, 456A
  60. Hohenleutner, 1997, Mycophenolate mofetil and cyclosporin treatment for recalcitrant pyoderma gangrenosum, Lancet, 350, 1748, 10.1016/S0140-6736(05)63571-4 · DOI
  61. Hovi, 1975, Rapid increase of phosphoribosyl pyrophosphate concentration after mitogenic stimulation of lymphocytes, FEBS Lett., 55, 291, 10.1016/0014-5793(75)81014-3 · DOI
  62. Hovi, 1977, Purine metabolism and control of cell proliferation, Ciba Found. Symp., 48, 225
  63. Huang, 1998, Effect of mycophenolate mofetil on anti-Thy-1 mesangial proliferative glomerulonephritis, J. Am. Soc. Nephrol., 9, 496A
  64. Hupe, 1986, IMP dehydrogenase from the intracellular parasitic protozoan Eimeria tenella and its inhibition by mycophenolic acid, J. Biol. Chem., 261, 8363, 10.1016/S0021-9258(19)83921-2 · doi:10.1016/s0021-9258(19)83921-2
  65. Ichimura, 1995, Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus, Virology, 211, 554, 10.1006/viro.1995.1437 · doi:10.1006/viro.1995.1437
  66. Isobe, 1992, Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1, Science, 255, 1125, 10.1126/science.1347662 · DOI · Paper page
  67. Jackson, 1977, Partial purification, properties and regulation of inosine 5′-phosphate dehydrogenase in normal and malignant rat tissues, Biochem. J., 166, 1, 10.1042/bj1660001 · DOI
  68. Keown, 1996, A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation, Transplantation, 61, 1029, 10.1097/00007890-199604150-00008 · DOI · Paper page
  69. Khanna, 1999, TGF-beta provides the rationale for the synergistic immunosuppression with rapamycin (RAPA), cyclosporine (CsA) and tacrolimus (TAC) calcineurin inhibitors sparing immunosuppression protocol, Transplantation, 67, S58, 10.1097/00007890-199904150-00235 · doi:10.1097/00007890-199904150-00235
  70. Koglin, 1999, Attenuated acute cardiac rejection in NOS2−/− recipients, Circulation, 99, 836, 10.1161/01.CIR.99.6.836 · DOI
  71. Koglin, 1998, NOS2 mediates opposing effects in models of acute and chronic cardiac rejection: insights from NOS2-knockout mice, Am. J. Pathol., 153, 1371, 10.1016/S0002-9440(10)65723-9 · DOI
  72. Konno, 1991, Expression of IMP dehydrogenase types I and II in Escherichia coli and distribution in normal human lymphocytes and leukemic cell lines, J. Biol. Chem., 266, 506, 10.1016/S0021-9258(18)52465-0 · doi:10.1016/s0021-9258(18)52465-0
  73. Larkin, 1999, Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease, Ophthomology, 106, 370, 10.1016/S0161-6420(99)90078-7 · DOI
  74. Laski, 1992, Selectins: interpreters of cell-specific carbohydrate information during inflammation, Science, 258, 964, 10.1126/science.1439808 · DOI · Paper page
  75. Laurent, 1996, Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and some substrates, Exp. Hematol., 24, 59
  76. Lee, 1990, Bioavailability improvement of mycophenolic acid through amino ester derivitization, Pharm. Res., 7, 161, 10.1023/A:1015828802490 · DOI · Paper page
  77. Leoni, 1978, Effects of cyclosporin A on human lymphocytes in culture, J. Lab. Clin. Immunol., 1, 67
  78. Li, 1998, Mycophenolate mofetil showed inhibitory effect on VCAM expression during successful treatment of diffuse proliferative lupus nephritis (SLE-DPGN) with vascular lesions, J. Am. Soc. Nephrol., 9, 153A
  79. Margolis, 1999, Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity, J. AIDS
  80. Maurizio, 1998, Mycophenolate mofetil (MMF) prevents acute rejection and assures high one-year graft survival also in the case of delayed graft function, J. Am. Soc. Nephrol., 9, 696A
  81. McMurray, 1998, Mycophenolate mofetil suppresses autoimmunity and mortality in the female (NZB×NZW)F1 mouse model of systemic lupus erythematosis, J. Rheumatol., 25, 2364
  82. Morris, 1990, Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T and B cell purine synthesis, Transplant. Proc., 22, 1659
  83. Morris, 1991, Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts, Transplant. Proc., 23, 19
  84. Mueller, 1998, Effect of mycophenolate mofetil on the in vivo infiltration of lymphocytes in the rat remnant kidney, Transplant. Proc., 30, 982, 10.1016/S0041-1345(98)00118-3 · doi:10.1016/s0041-1345(98)00118-3
  85. Mulkins, 1992, Mycophenolic acid inhibits the degranulation of rat peritoneal mast cells, Cell. Immunol., 141, 508, 10.1016/0008-8749(92)90167-N · doi:10.1016/0008-8749(92)90167-n
  86. Nachman, 1997, Mycophenolate mofetil therapy in patients with cyclophosphamide-(CyP) resistant or relapsing diffuse proliferative lupus nephritis (SLE-DPGN), J. Am. Soc. Nephrol., 9, 94A
  87. Nadeau, 1996, Sequential cytokine expression in renal allografts in rats immunosuppressed with maintenance cyclosporine or mycophenolate mofetil, Transplantation, 62, 1363, 10.1097/00007890-199611150-00034 · DOI
  88. Nagai, 1992, Proliferation-linked regulation of the type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells, Cancer Res., 52, 258
  89. Nagy, 1993, Effect of mycophenolate mofetil (RS-61443) on cytokine production: inhibition of superantigen-induced cytokines, Immunopharmacology, 26, 11, 10.1016/0162-3109(93)90062-U · doi:10.1016/0162-3109(93)90062-u
  90. Natsumeda, 1990, Two distinct cDNAs for human IMP dehydrogenase, J. Biol. Chem., 265, 5292, 10.1016/S0021-9258(19)34120-1 · doi:10.1016/s0021-9258(19)34120-1
  91. Nehme, 1998, The role of mycophenolate mofetil in the management of refractory inflammatory bowel disease (IBD), Gastroenterology, 114, A1049, 10.1016/S0016-5085(98)84267-4 · doi:10.1016/s0016-5085(98)84267-4
  92. Neurath, 1998, Randomized trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease, Gastroenterology, 114, A1050
  93. Neyts, 1998, The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo, Antimicro. Agents Chemother., 42, 216, 10.1128/AAC.42.2.216 · doi:10.1128/aac.42.2.216
  94. Neyts, 1998, The antiherpesvirus activity of H2G is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil, Antimicro. Agents Chemother., 42, 3285, 10.1128/AAC.42.12.3285 · doi:10.1128/aac.42.12.3285
  95. Neyts, 1996, Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infection, Antiviral Res., 30, 125, 10.1016/0166-3542(96)89697-5 · doi:10.1016/0166-3542(96)89697-5
  96. Noronha, 1998, Enhanced interstitial expression of angiotensin II and TGF-β in the renal ablation model: effect of mycophenolate mofetil, J. Am. Soc. Nephrol., 9, 618A
  97. Nousari, 1998, Successful therapy for bullous pemphigoid with mycophenolate mofetil, J. Am. Acad. Dermatol., 39, 497, 10.1016/S0190-9622(98)70334-2 · doi:10.1016/s0190-9622(98)70334-2
  98. Nousari, 1998, The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum, Arch. Dermatol., 134, 1509, 10.1001/archderm.134.12.1509 · doi:10.1001/archderm.134.12.1509
  99. Nowack, 1997, Mycophenolate mofetil for systemic vasculitis and IgA nephropathy, Lancet, 349, 774, 10.1016/S0140-6736(05)60198-5 · doi:10.1016/s0140-6736(05)60198-5
  100. O'Gara, 1997, IMP dehydrogenase from Pneumocystis carinii as a potential drug target, Antimicro. Agents Chemother., 41, 40, 10.1128/AAC.41.1.40 · DOI
  101. O'Hair, 1994, Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil, Ann. Thorac. Surg., 58, 1311, 10.1016/0003-4975(94)91902-X · doi:10.1016/0003-4975(94)91902-x
  102. Ozchgfhj, 1997, Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to the provocative effects of tacrolimus, sirolimus and dexamethasone, J. Infect. Dis., 175, 901, 10.1086/513988 · DOI
  103. Pardo-Mindán, 1999, Decrease of apoptosis rate in patients treated with mycophenolate mofetil, Nephron, 82, 232, 10.1159/000045407 · doi:10.1159/000045407
  104. Paul, 1998, Donor pretreatment with mycophenolate mofetil protects against ischemia–reperfusion injury, Transplantation, 65, 1193
  105. Paul, 1996, Nitric oxide synthase inhibition is associated with decreased survival of cardiac allografts in the rat, Transplantation, 65, 1193, 10.1097/00007890-199610270-00032 · doi:10.1097/00007890-199610270-00032
  106. Penny, 1998, Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition, J. Am. Soc. Nephrol., 9, 2272, 10.1681/ASN.V9122272 · doi:10.1681/asn.v9122272
  107. Peters, 1982, Effects of adenosine and deoxyadenosine on PHA stimulation of lymphocytes of man, horse and pig, Int. J. Biochem., 14, 377, 10.1016/0020-711X(82)90023-4 · doi:10.1016/0020-711x(82)90023-4
  108. Pickenacker, 1998, Dyshidrotic eczema treated with mycophenolate mofetil, Arch. Dermatol., 134, 378, 10.1001/archderm.134.3.378 · doi:10.1001/archderm.134.3.378
  109. Platz, 1991, RS-61443 for reversal of acute rejection in canine renal allografts, Surgery, 110, 736
  110. Platz, 1998, Indications for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation, Transplant. Proc., 30, 1468, 10.1016/S0041-1345(98)00319-4 · doi:10.1016/s0041-1345(98)00319-4
  111. Platz, 1990, RS-61443, a new, potent immuno-suppressive agent, Transplantation, 51, 27, 10.1097/00007890-199101000-00003 · DOI · Paper page
  112. Räisänen-Sokolowski, 1995, Mycophenolate mofetil (MMF, RS-61443) inhibits proliferation of rat aortic allografts, Transplant. Immunol., 3, 342, 10.1016/0966-3274(95)80021-2 · DOI
  113. Reis, 1998, Mycophenolate mofetil in ocular immunological disorders. A survey of the literature with 3 case reports, Klin. Monatsbl. Augenheilkd., 213, 257, 10.1055/s-2008-1034985 · doi:10.1055/s-2008-1034985
  114. Richman, 1987, Failure of dideoxynucleosides to inhibit HIV replication in cultured human macrophages, J. Exp. Med., 166, 1144, 10.1084/jem.166.4.1144 · DOI
  115. Romero, 1999, Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats, Kidney Int., 55, 945, 10.1046/j.1523-1755.1999.055003945.x · DOI · Paper page
  116. Rosenberg, 1992, Cellular basis of skin graft rejection: an in vivo model of immune-mediated tissue destruction, Annu. Rev. Immunol., 10, 333, 10.1146/annurev.iy.10.040192.002001 · DOI · Paper page
  117. Schiff, 1998, CellCept (mycophenolate mofetil-MMF), a new treatment for RA: a 12-week, double-blind, randomized, placebo-controlled withdrawal trial, Arthritis Rheum., 41, S364
  118. Senda, 1995, Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells, Transplantation, 60, 1143, 10.1097/00007890-199511270-00015 · DOI
  119. Shaffer, 1992, Small bowel transplantation in rats using RS-61443: effect on GVHD and rejections, Transplant. Proc., 24, 1159
  120. Shaffer, 1993, Prevention of graft-versus-host disease by RS-61443 in two different rodent models, Transplantation, 55, 221, 10.1097/00007890-199301000-00046 · doi:10.1097/00007890-199301000-00046
  121. Shears, 1997, Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis, J. Clin. Invest., 100, 2035, 10.1172/JCI119736 · DOI · Paper page
  122. Shoji, 1994, Effect of topical preparation of mycophenolic acid on experimental allergic contact dermatitis of guinea-pigs induced by dinitrofluorobenzene, J. Pharm. Pharmacol., 46, 643, 10.1111/j.2042-7158.1994.tb03874.x · DOI
  123. Sintchak, 2000, The structure of inosine monophosphate dehydrogenase and the design of novel inhibitors, Immunopharmacology, 47, 163, 10.1016/S0162-3109(00)00193-4 · doi:10.1016/s0162-3109(00)00193-4
  124. Steele, 1993, Effects of immunosuppressive therapy on the rat aortic allograft model, Transplant. Proc., 25, 754
  125. Stojanovic, 1996, Enhanced renal allograft rejection by inhibitors of alloreactivity, Lab. Invest., 74, 496
  126. Szabolcs, 1996, Apoptosis of cardiac myocytes during cardiac allograft rejection. Relation to inhibition of nitric oxide synthase, Circulation, 94, 1665, 10.1161/01.CIR.94.7.1665 · DOI · Paper page
  127. Szabolcs, 1998, Apoptosis and increased expression of inducible nitric oxide synthase in human allograft rejection, Transplantation, 65, 804, 10.1097/00007890-199803270-00007 · DOI
  128. Thomson, 1993, Effects of combined administration of FK-506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T-cell activation molecule expression in human mixed lymphocyte cultures, Transplant. Immunol., 1, 146, 10.1016/0966-3274(93)90009-W · DOI
  129. Tutschka, 1979, Use of cyclosporin A in allogeneic bone marrow transplantation in the rat, Nature, 280, 148, 10.1038/280148a0 · doi:10.1038/280148a0
  130. Van Bruggen, 1998, Attenuation of murine lupus nephritis by mycophenolate mofetil, J. Am. Soc. Nephrol., 9, 1407, 10.1681/ASN.V981407 · DOI
  131. Verham, 1987, Purification, characterization and kinetic analysis of inosine-5′monophosphate dehydrogenase of Trichomonas foetus, Mol. Biochem. Parasitol., 24, 1, 10.1016/0166-6851(87)90110-1 · doi:10.1016/0166-6851(87)90110-1
  132. Wang, 1998, Alterations in mRNA for inducible endothelial nitric oxide synthase and plasma nitric oxide with rejection and/or infection of allotransplanted lungs, Transplantation, 66, 567, 10.1097/00007890-199809150-00003 · doi:10.1097/00007890-199809150-00003
  133. Wang, 1999, Mycophenolate mofetil protects against renal ischemia–reperfusion injury by inhibiting osteopontin and ICAM-1 expression, Transplantation, 67, 537, 10.1097/00007890-199904150-00152 · doi:10.1097/00007890-199904150-00152
  134. Wang, 1984, Differential effects of inhibitors of purine metabolism on two trichomonad species, Biochem. Pharmacol., 33, 1323, 10.1016/0006-2952(84)90187-4 · doi:10.1016/0006-2952(84)90187-4
  135. Watarai, 1999, Nitric oxide production in renal transplant recipients and iNOS expression in renal allografts, Transplantation, 67, S9, 10.1097/00007890-199904150-00039 · doi:10.1097/00007890-199904150-00039
  136. Waters, 1993, Mycophenolic acid and some antioxidants induce differentiation of monocytic lineage cells and augment production of the IL-1 receptor antagonist, Ann. N. Y. Acad. Sci., 696, 185, 10.1111/j.1749-6632.1993.tb17151.x · DOI
  137. Wei, 1999, Mycophenolic acid (MPA) inhibits the over-expression of osteopontin and ICAM-1 proteins in ischemia/reperfusion injury, J. Am. Soc. Nephrol., 9, 660A
  138. Weimer, 1999, Monocyte responses in patients with chronic renal transplant rejection: beneficial effects of MMF-based immunosuppression, Transplantation, 67, 27, 10.1097/00007890-199904150-00111 · doi:10.1097/00007890-199904150-00111
  139. Whitcup, 1993, Treatment of autoimmune uveitis, Am. NY Acad. Sci., 696, 307, 10.1111/j.1749-6632.1993.tb17166.x · doi:10.1111/j.1749-6632.1993.tb17166.x
  140. Winklhofer, 1999, Mycophenolate inhibits nitric oxide (NO) production via iNOS in renal allograft recipients, Transplantation, 67, S218, 10.1097/00007890-199904150-00872 · doi:10.1097/00007890-199904150-00872
  141. Wolberg, 1988, Antipurines and purine metabolism, Handb. Exp. Pharmacol., 85, 517, 10.1007/978-3-642-73217-1_24 · DOI
  142. Wolff, 1998, Treatment of high risk chronic GVHD with FK506, mycophenolate mofetil (MMF) and methylprednisolone (MP), Br. J. Haematol., 102, 210
  143. Worrall, 1999, Time course and cellular localization of indicible nitric oxide synthases expression during cardiac allograft rejection, Ann. Thorac. Surg., 67, 716, 10.1016/S0003-4975(98)01346-0 · doi:10.1016/s0003-4975(98)01346-0
  144. Wu, 1994, Mycophenolate mofetil: mechanisms of action, Perspect. Drug Discov. Design, 2, 185, 10.1007/BF02171743 · doi:10.1007/bf02171743
  145. Yamaguchi, 1999, Peroxynitrite formation during rat hepatic allograft rejection, Hepatology, 29, 777, 10.1002/hep.510290354 · DOI
  146. Yu, 1998, Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical marrow grafts, Blood, 91, 2581, 10.1182/blood.V91.7.2581 · doi:10.1182/blood.v91.7.2581
  147. Zeeh, 1998, Mycophenolate mofetil reduces tissue damage in an experimental model of colitis in rats, Gastroenterology, 114, A1122
  148. Zimmer-Molsberger, 1997, Mycophenolate mofetil for severe autoimmune haemolytic anaemia, Lancet, 350, 1003, 10.1016/S0140-6736(05)64068-8 · DOI
  149. Zimmerman, 1998, Mycophenolate mofetil (MMF) treatment of idiopathic membranous nephropathy (IMN), J. Am. Soc. Nephrol., 9, 103A
  150. Ziolo, 1998, Myocytes isolated from rejecting transplanted hearts exhibit reduced basal shortening which is reversible by aminoguanidine, J. Mol. Cell Cardiol., 30, 1009, 10.1006/jmcc.1998.0665 · DOI
  151. Ziswiler, 1998, Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis, J. Am. Soc. Nephrol., 9, 2055, 10.1681/ASN.V9112055 · doi:10.1681/asn.v9112055

Cited by

See all 1,433

Metadata

Authors
Allison, A. C., & Eugui, E. M.
Venue
Immunopharmacology
Publisher
Elsevier BV
Published
2000-05
Volume
47
Issue
2-3
Pages
85-118
ISSN
0162-3109 (ISSN-L)
DOI
10.1016/s0162-3109(00)00188-0
OpenAlex
W2061904336
Cited by
1,433
References
1
FWCI
10.59
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mycophenolate mofetil and its mechanisms of action. https://app.cochat.ai/papers/10.1016/s0162-3109(00)00188-0
The paper
Allison, A. C., & Eugui, E. M. (2000). Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. https://doi.org/10.1016/s0162-3109(00)00188-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.